Table 1.
Biologic drugs targeting IL-23 and IL-17
| Drug | Drug company | Drug type | Target | Current status for plaque psoriasis |
|---|---|---|---|---|
| Ustekinumab (Stelara®, CNTO1275) | Janssen | Human monoclonal antibody | P40 subunit of IL-23 and IL-12 | Approved |
| Briakinumab (ABT 874) | Abbott | Human monoclonal antibody | P40 subunit of IL-23 and IL-12 | Terminated |
| Tildrakizumab (MK-3222) | Merck | Humanized monoclonal antibody | p19 subunit of IL-23 | Phase III |
| BI 655066 |
Boehringer Ingelheim |
Monoclonal antibody | p19 subunit of IL-23 | Phase II |
| Guselkumab (CNTO 1959) | Janssen | Human IgG1λ monoclonal IL-23 antibody | p19 subunit of IL-23 | Phase III |
| Secukinumab (Cosentyx®, AIN457) | Novartis | Human monoclonal antibody | IL-17A | Approved |
| Ixekizumab (LY2439821) | Eli Lilly | Humanized monoclonal antibody | IL-17A | Phase III |
| Brodalumab (AMG 827) | Amgen/AstraZeneca/Valeant | Human monoclonal antibody | IL-17 receptor A | No ongoing studies |
| ABT-122 | AbbVie | Dual variable domain antibody | IL-17 and TNF-α | Phase II |
IL interleukin, TNF tumor necrosis factor